KOGENATE® Bayer is a factor VIII (FVIII) concentrate product produced by recombinant DNA technology.1

It is indicated for the treatment and prophylaxis of bleeding in adults, adolescents and children of all ages with haemophilia A (congenital factor VIII deficiency).1

Bayer has 25 years of clinical experience with recombinant FVIII (rFVIII), with more than 20 billion units infused and zero confirmed cases of pathogen transmission across all rFVIII products.2


  1. KOGENATE® Bayer Summary of Product Characteristics, September 2013.
  2. Data on File, KOGENATE® Bayer 0142 (Bayer HealthCare 2013).